Volume 14 Supplement 1
Publication charges for this supplement were funded by 3P Solution, Milan, Italy. PAA has acted in a consultant/advisory role for BMS, Roche-Genentech, MSD, Ventana, Novartis and Amgen and has received research funding from BMS, Roche-Genentech and Ventana. The other Supplement Editors declare that they have no competing interests.
Naples, Italy1-5 December 2015
Edited by Paolo A Ascierto, Francesco M Marincola and Nicolar Mozzillo.
MELANOMA BRIDGE 2015
Citation Impact
8.440 - 2-year Impact Factor (2021)
7.552 - 5-year Impact Factor (2021)
1.582 - Source Normalized Impact per Paper (SNIP)
1.570 - SCImago Journal Rank (SJR)
Speed
8 days to first decision for all manuscripts (Median)
45 days to first decision for reviewed manuscripts only (Median)
Usage
4,155,992 Downloads (2021)
7,409 Altmetric mentions (2021)